Laurus is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Initiatives are in place to develop a Finished Dosage Forms capabilities on the back of existing strengths in APIs. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses.
Company: | Laurus Labs Limited | ||
Headquarters Address: | 2nd Floor Serene Towers, Rd No 5, Banjarahills, | ||
Hyderabad 500034 | |||
India | |||
Main Telephone: | +91 40 3980 4333 | ||
Website: | www.lauruslabs.com | ||
Ticker/ISIN: | 540222(MUMBAI)/INE947Q01010 | ||
LAURUSLABS(NSI)/INE947Q01010 | |||
Type of Organization: | Public | ||
Industry: | Pharmaceutical | ||
Earnings Release Dates: | 4th Quarter: May 18, 2017 | ||
Key Executives: | CEO: Satyanarayana Chava | ||
CFO: V V Ravi Kumar | |||
Public Relations | |||
Contact: | Pavan Kumar | ||
Phone: | +91 40 3980 4380 | ||
Email: | pavankumar.n@lauruslabs.com |
View source version on businesswire.com: http://www.businesswire.com/news/home/20170518005424/en/